Several studies demonstrated that the combination of Ara-C with the SMO inhibitor cyclopamine or the GLI inhibitor GANT-61 significantly enhanced the sensitivity of AML cell lines and primary CD34+ AML cells to Ara-C [21,33,34]. This evidence concerns the gene GLI1 and acute myeloid leukemia.